Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Claremont Adds Partner Focused on Health, Energy and Big Data

Claremont lures Harsh Patel from Foundation Capital.

Claremont Creek Ventures will announce later today it added Harsh Patel as a partner at the Oakland venture capital firm, where he will scout for promising startups in health, clean energy and other fields.

Specifically, he will focus on companies applying big data, the catchall term for mining vast amounts of information to arrive at new insights and more accurate predictions in these sectors.

This has long been a focus area for Patel as a venture capitalist, angel investor, entrepreneur or executive at RRE Ventures, In-Q-Tel, Bina Technologies, Orbit Commerce and, most recently, Foundation Capital.

As a general partner at In-Q-Tel, the investment outfit affiliated with the Central Intelligence Agency, he led an early-stage investment in Palantir Technologies, the controversial company that helps three-letter intelligence agencies connect the dots in massive data sets.

Patel was also the president of Bina Technologies, which applies data analytics to the human genome, crunching information that can hold clues to health risks and personalized treatments.

In an interview at the early-stage investment firm’s offices, in the historic Rotunda Building near Oakland’s City Hall, Patel said he will be looking for investment opportunities in highly regulated spaces. These may carry significant risks — but also promise big upsides for companies that offer more efficient ways of doing things.

“The big pieces, the gnarly pieces, are energy, health care, government and defense,” he said. “Those aren’t always attractive venture capital areas, but there’s enormous spend.”

Claremont managing director Nat Goldhaber said Patel was a natural fit because his expertise and interests overlap significantly with that of the firm. CCV has long invested heavily in clean energy and medical tech companies, including Alphabet Energy, Blue Pillar, CellScope, DNAnexus and Natera.

He also said they brought on Patel as a new director to handle a surge in deal flow. Claremont made 13 investments last year and enjoyed a lucrative exit when Outerwall (better known by its earlier name, Coinstar) acquired portfolio company ecoATM for $350 million.

“We’re seeing so much great stuff and he had a great background in both genetics and in clean tech as an investor and as an [executive],” Goldhaber said. “That is one of the hallmarks for the foundation of this firm: People with real hands-on experience running things.”

This article originally appeared on Recode.net.

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh